MedTrace Logo

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

NCT01172418 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of the present study is to determine which antibody induction regimen will result in a safer and more effective method to use with steroid avoidance in renal transplant recipients. Patients receiving either first cadaveric or non-HLA identical living donor kidney transplants will be preoperatively randomized into 2 groups.

Conditions

  • Transplant; Failure, Kidney

Interventions

DRUG

Alemtuzumab

Alemtuzumab used as part of combined Induction.

DRUG

Daclizumab

Daclizumab used as part of combined induction.

DRUG

Thymoglobulin

Thymoglobulin used as part of combined induction.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172418 on ClinicalTrials.gov